Print this article
- 03/13/2018

Polypeptide Therapeutic Solutions and PMC Isochem sign business and technology collaboration agreement in the field of Cosmetic and Therapeutic Polypeptide

Chimica Oggi-Chemistry Today

Under the agreement, Polypeptide Therapeutic Solutions will use proprietary technology and research capabilities to offer contract research services from the polypeptide design up to delivery of small quantity of polymer and PMC Isochem will use GMP production facility for clinical batch and commercial supply. In addition, PMC Isochem develops and supplies the strategic high quality Aminoacid N-CarboxyAnhydride raw materials.

”This collaboration with Polypeptide Therapeutic Solutions is an important strategic move for PMC Isochem as it opens a new area of development in the pharmaceutical and cosmetic market. It also represents a move forward in the value chain starting from our unique offer of Aminoacid N-CarboxyAnhydride” commented Dr Raj Chakrabarti, ExecutiveVice President of PMC Group International.

“This collaboration starts from a solid ground of 3 years of experience demonstrating the global value and synergies resulting from this alliance” says Dr. Yves Robin R&D Director at PMC Isochem “It represents a unique one stop shop offer from the strategic monomer to polypeptide building and from research to GMP production”

“We have developed with PMC ISOCHEM a team that is able to deliver value added solutions, putting together a unique team with knowledge and technology that enables our customers to accelerate time-to-market” says Jose Vicente Pons, Chief Executive Officer at PTS.

“The synergies developed between our companies during the last years becomes now a solid strategic movement towards a global solution in polypeptide-based materials” commented Vicent J. Nebot, Chief Technical Officer at PTS “this collaboration represents a unique offer for a growing field, providing to our partners a solid translation from early development to the market”.    

http://pmcisochem.fr/